Skip to main content
All lobbying filings

RARE DISEASE COMPANY COALITION

RARE DISEASE COMPANY COALITION filed a Q2 report for RARE DISEASE COMPANY COALITION on July 18, 2025.

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

All filings by RARE DISEASE COMPANY COALITION · Everything RARE DISEASE COMPANY COALITION has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 18, 2025
Expenses
$70,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Budget/Appropriations

HR 1 - Big Beautiful Bill Act

Pharmacy

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities

Science/Technology

Executive Order 14297 - Impact of EO on Rare Disease Innovation Rare Disease Policy

Trade (domestic/foreign)

Sec. 232 Pharmaceutical Tariffs

 Bills named in this filing 4

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem